Based on the key measurements obtained from MiMedx's financial statements, MiMedx Group is performing exceptionally good at this time. It has a great odds to report excellent financial results in January. At this time, MiMedx's Cash is most likely to increase significantly in the upcoming years. The MiMedx's current Non Current Assets Total is estimated to increase to about 78.5 M, while Other Current Liabilities is projected to decrease to roughly 22.9 M. Key indicators impacting MiMedx's financial strength include:
The financial analysis of MiMedx is a critical element in measuring its lifeblood. Investors should not minimize MiMedx's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
MiMedx competes with Monte Rosa, Design Therapeutics, Werewolf Therapeutics, Ikena Oncology, and Stoke Therapeutics. MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. Mimedx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 811 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining MiMedx's current stock value. Our valuation model uses many indicators to compare MiMedx value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across MiMedx competition to find correlations between indicators driving MiMedx's intrinsic value. More Info.
MiMedx Group is considered to be number one stock in return on equity category among its peers. It is regarded second in return on asset category among its peers reporting about 0.29 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for MiMedx Group is roughly 3.40 . At this time, MiMedx's Return On Equity is most likely to increase significantly in the upcoming years. Comparative valuation analysis is a catch-all technique that is used if you cannot value MiMedx by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
MiMedx Group Systematic Risk
MiMedx's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. MiMedx volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on MiMedx Group correlated with the market. If Beta is less than 0 MiMedx generally moves in the opposite direction as compared to the market. If MiMedx Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one MiMedx Group is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of MiMedx is generally in the same direction as the market. If Beta > 1 MiMedx moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in MiMedx Stock are looking for potential investment opportunities by analyzing not only static indicators but also various MiMedx's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of MiMedx growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of MiMedx help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of MiMedx Group. We use our internally-developed statistical techniques to arrive at the intrinsic value of MiMedx Group based on widely used predictive technical indicators. In general, we focus on analyzing MiMedx Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build MiMedx's daily price indicators and compare them against related drivers.
When running MiMedx's price analysis, check to measure MiMedx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MiMedx is operating at the current time. Most of MiMedx's value examination focuses on studying past and present price action to predict the probability of MiMedx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MiMedx's price. Additionally, you may evaluate how the addition of MiMedx to your portfolios can decrease your overall portfolio volatility.